[Federal Register Volume 60, Number 82 (Friday, April 28, 1995)]
[Notices]
[Page 20999]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-10429]



[[Page 20999]]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Docket No. 95M-0057]


Medtronic CardioRhythm; Premarket Approval of Atakr Radio 
Frequency Catheter Ablation System

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing its 
approval of the application by Medtronic CardioRhythm, San Jose, CA, 
for premarket approval, under the Federal Food, Drug, and Cosmetic Act 
(the act), of the Atakr Radio Frequency Catheter Ablation System. After 
reviewing the recommendation of the Circulatory System Devices Panel, 
FDA's Center for Devices and Radiological Health (CDRH) notified the 
applicant, by letter of February 9, 1995, of the approval of the 
application.

DATES: Petitions for administrative review by May 30, 1995.

ADDRESSES: Written requests for copies of the summary of safety and 
effectiveness data and petitions for administrative review to the 
Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 
1-23, 12420 Parklawn Dr., Rockville, MD 20857.
FOR FURTHER INFORMATION CONTACT: Mark Massi, Center for Devices and 
Radiological Health (HFZ-450), Food and Drug Administration, 9200 
Corporate Blvd., Rockville, MD 20850, 301-443-8609.

SUPPLEMENTARY INFORMATION: On August 26, 1993, Medtronic CardioRhythm, 
San Jose, CA 95134, submitted to CDRH an application for premarket 
approval of the Atakr Radio Frequency Catheter Ablation System. The 
device is a radio frequency power cardiac catheter ablation system, and 
it is indicated for interruption of accessory atrioventricular (AV) 
conduction pathways associated with tachycardia, for the treatment of 
AV nodal re-entrant tachycardia, and for creation of complete AV block 
in patients with a difficult to control ventricular response to an 
atrial arrhythmia.
    On December 5, 1994, the Circulatory System Devices Panel of the 
Medical Devices Advisory Committee, an FDA advisory committee, reviewed 
and recommended approval of the application. On February 9, 1995, CDRH 
approved the application by a letter to the applicant from the Director 
of the Office of Device Evaluation, CDRH.
    A summary of the safety and effectiveness data on which CDRH based 
its approval is on file in the Dockets Management Branch (address 
above) and is available from that office upon written request. Requests 
should be identified with the name of the device and the docket number 
found in brackets in the heading of this document.

Opportunity for Administrative Review

    Section 515(d)(3) of the act (21 U.S.C. 360e(d)(3)) authorizes any 
interested person to petition, under section 515(g) of the act, for 
administrative review of CDRH's decision to approve this application. A 
petitioner may request either a formal hearing under part 12 (21 CFR 
part 12) of FDA's administrative practices and procedures regulations 
or a review of the application and CDRH's action by an independent 
advisory committee of experts. A petition is to be in the form of a 
petition for reconsideration under Sec. 10.33(b) (21 CFR 10.33(b)). A 
petitioner shall identify the form of review requested (hearing or 
independent advisory committee) and shall submit with the petition 
supporting data and information showing that there is a genuine and 
substantial issue of material fact for resolution through 
administrative review. After reviewing the petition, FDA will decide 
whether to grant or deny the petition and will publish a notice of its 
decision in the Federal Register. If FDA grants the petition, the 
notice will state the issue to be reviewed, the form of review to be 
used, the persons who may participate in the review, the time and place 
where the review will occur, and other details.
    Petitioners may, at any time on or before (insert date 30 days 
after date of publication in the Federal Register), file with the 
Dockets Management Branch (address above) two copies of each petition 
and supporting data and information, identified with the name of the 
device and the docket number found in brackets in the heading of this 
document. Received petitions may be seen in the office above between 9 
a.m. and 4 p.m., Monday through Friday.
    This notice is issued under the Federal Food, Drug, and Cosmetic 
Act (secs. 515(d), 520(h) (21 U.S.C. 360e(d), 360j(h))) and under 
authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) 
and redelegated to the Director, Center for Devices and Radiological 
Health (21 CFR 5.53).

    Dated: April 3, 1995.
Joseph A. Levitt,
Deputy Director for Regulations Policy, Center for Devices and 
Radiological Health.
[FR Doc. 95-10429 Filed 4-27-95; 8:45 am]
BILLING CODE 4160-01-F